デフォルト表紙
市場調査レポート
商品コード
1427058

過体重治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 治療別、流通チャネル別、地域別

Overweight Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

出版日
ページ情報
英文 245 Pages
納期
2～5営業日
過体重治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 治療別、流通チャネル別、地域別
出版日: 2024年02月01日
発行: Fairfield Market Research
ページ情報: 英文 245 Pages
納期: 2～5営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

世界の過体重治療の市場規模は、病的な肥満人口における意識の高まり、規制機関と医薬品メーカーとの戦略的提携、肥満関連疾患の有病率の上昇など、さまざまな要因が重なって力強い成長を遂げています。同市場は、2024年に340億米ドルとなるとみられ、2031年末までに740億米ドルという驚異的な評価額に達する見込みです。

COVID-19の大流行は、肥満者が様々な健康合併症に対して脆弱であることを強調し、過体重治療ソリューションに対する需要の急増を促しています。米国心臓協会が強調しているように、心血管疾患、II型糖尿病、脂質異常症、睡眠障害、高血圧などの疾患は肥満と直接関連しています。このような認識により、減量ソリューションを求める個人の間で、栄養補助食品、薬物治療、運動、脂肪吸引のような外科的介入への傾倒が高まっています。

米国食品医薬品局（FDA）と医薬品メーカーの協力により、革新的な過体重治療製品の承認プロセスが大幅に迅速化されました。2012年に制定されたUSFDA安全性革新法は、医薬品メーカーに深刻な病状に対する新規治療法を開発するインセンティブを与え、市場開発を促進する環境を整備しました。このような規制上の支援は、先進国における座りがちなライフスタイルの蔓延と相まって、今後数年間、世界の過体重治療市場を前進させるものと期待されます。

有望な成長軌道にもかかわらず、市場は薬剤開発や外科手術のコストが高いといった課題に直面しています。研究開発および臨床試験に必要な多額の財政投資が、市場拡大の障壁となっています。さらに、特定の医薬品に関連する安全性への懸念が製品の回収や撤回につながり、消費者の信頼を低下させ、市場の成長を妨げています。

当レポートでは、世界の過体重治療市場について調査し、市場の概要とともに、治療別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の過体重治療市場の見通し、2018年～2031年

  • 世界の過体重治療市場の見通し、治療別、金額（10億米ドル）、2018年～2031年
  • 世界の過体重治療市場の見通し、流通チャネル別、金額（10億米ドル）、2018年～2031年
  • 世界の過体重治療市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米の過体重治療市場の見通し、2018年～2031年

第5章 欧州の過体重治療市場の見通し、2018年～2031年

第6章 アジア太平洋の過体重治療市場の見通し、2018年～2031年

第7章 ラテンアメリカの過体重治療市場の見通し、2018年～2031年

第8章 中東・アフリカの過体重治療市場の見通し、2018年～2031年

第9章 競合情勢

  • 製品別と流通チャネル別のヒートマップ
  • 企業の市場シェア分析、2022年
  • 競合ダッシュボード
  • 企業プロファイル
    • Novo Nordisk A/S
    • VIVUS LLC
    • AstraZeneca
    • Currax Pharmaceuticals LLC
    • Spansules Pharmatech Pvt Ltd
    • Atkins Nutritional Inc
    • Apollo Endosurgery, Inc
    • Herbalife Nutrition Ltd.
    • SMP Nutra
    • Allurion Technologies
    • ReShape Lifesciences, Inc

第10章 付録

目次

Growing Awareness and Strategic Partnerships Drive Demand for Overweight Treatment Solutions

The global overweight treatment market is witnessing robust growth, fueled by a combination of factors including increased awareness among the morbidly obese population, strategic collaborations between regulatory bodies and drug manufacturers, and the rising prevalence of obesity-related diseases. According to the latest report by Fairfield Market Research, the market, valued at US$ 34 billion in 2024, is expected to reach a staggering valuation of US$ 74 billion by the end of 2031.

Increasing Awareness among the Morbidly Obese Population

The COVID-19 pandemic has underscored the vulnerability of obese individuals to various health complications, prompting a surge in demand for overweight treatment solutions. Diseases such as cardiovascular ailments, type II diabetes, dyslipidemia, sleep disorders, and hypertension are directly linked to obesity, as highlighted by the American Heart Association. This awareness has led to a growing inclination towards nutrition supplements, drug treatments, exercise, and surgical interventions like liposuction among individuals seeking weight loss solutions.

Cooperation between Regulatory Bodies and Drug Manufacturers

The collaboration between the U.S. Food and Drug Administration (FDA) and drug manufacturers has significantly expedited the approval process for innovative overweight treatment products. The USFDA Safety Innovations Act of 2012 has incentivized manufacturers to develop novel therapies for serious medical conditions, thereby fostering a conducive environment for market growth. This regulatory support, coupled with the increasing prevalence of sedentary lifestyles in developed nations, is expected to propel the global overweight treatment market forward in the coming years.

Challenges Hindering Market Progress

Despite the promising growth trajectory, the market faces challenges such as the high cost of drug development and surgical procedures. The substantial financial investment required for research, development, and clinical trials poses a barrier to market expansion. Moreover, safety concerns associated with certain drugs have led to product recalls and withdrawals, dampening consumer confidence and hindering market growth.

Country-wise Insights: Opportunities Abound in Key Markets

United States: With a significant share in the North American market, the U.S. remains a lucrative hub for overweight treatment solutions. The rising incidence of obesity-related diseases and increasing awareness among consumers are driving the demand for weight management resources, including dietary supplements and lifestyle modifications.

Germany: The European overweight treatment market is witnessing steady growth, with Germany emerging as a key player. High prevalence of obesity-related diseases, coupled with collaborative efforts by organizations like the German Obesity Alliance, is driving market expansion, particularly in the area of obesity treatment centers.

China: Economic growth and changing lifestyle habits have contributed to a surge in obesity rates in China. The market for overweight treatment solutions is poised for rapid expansion, with a shift towards modern interventions such as medications and surgery from traditional herbal remedies.

India: India presents immense growth opportunities in the overweight treatment market, fueled by rising obesity rates and government initiatives promoting healthy lifestyles. Initiatives such as the Ayushman Bharat Scheme and the inclusion of bariatric surgery under insurance coverage are expected to drive market growth in the country.

Competitive Landscape: Key Players Driving Innovation

Leading companies in the overweight treatment market are continuously innovating to maintain their competitive edge. Strategic initiatives such as new product launches, portfolio upgrades, and clinical research activities are commonplace. Additionally, consolidation activities through collaborations and acquisitions are enabling players to strengthen their market presence and expand their product offerings.

Key Companies Profiled:

  • Novo Nordisk A/S
  • VIVUS LLC
  • AstraZeneca
  • Currax Pharmaceuticals LLC
  • Spansules Pharmatech Pvt Ltd
  • Atkins Nutritional Inc
  • Apollo Endosurgery, Inc
  • Herbalife Nutrition Ltd.
  • SMP Nutra
  • Allurion Technologies
  • ReShape Lifesciences, Inc
  • Bariatric Solutions GmbH
  • Silimed
  • ENDALIS
  • Districlass Medical
  • Medtronic.

Key Segments Covered in Overweight Treatment Industry Research

Overweight Treatment Market by Treatment:

  • Drug Treatment
    • Bupropion and Naltrexone
    • Orlistat
    • Phentermine and Topiramate
    • Liraglutide
  • Others
  • Supplements
  • Medical Devices / Implants
    • Gastric Balloons
    • Gastric Bands
    • Stapling Devices

Overweight Treatment Market by Distribution Channel:

  • Institutional Sales
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
  • Retail Sales
    • Retail Pharmacy
    • Drug Stores
    • Supermarkets / Hypermarkets
    • Health & Beauty Stores
  • Online Sales

Overweight Treatment Market by Region:

  • North America Overweight Treatment Market
  • Latin America Overweight Treatment Market
  • Europe Overweight Treatment Market
  • South Asia Overweight Treatment Market
  • East Asia Overweight Treatment Market
  • Oceania Overweight Treatment Market
  • Middle East & Africa Overweight Treatment Market

Table of Contents

1. Executive Summary

  • 1.1. Global Overweight Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Overweight Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
        • 3.1.1.1.1. Drug Treatment
          • 3.1.1.1.1.1. Bupropion and Naltrexone
          • 3.1.1.1.1.2. Orlistat
          • 3.1.1.1.1.3. Phentermine and Topiramate
          • 3.1.1.1.1.4. Liraglutide
        • 3.1.1.1.2. Others
        • 3.1.1.1.3. Supplements
        • 3.1.1.1.4. Medical Devices / Implants
          • 3.1.1.1.4.1. Gastric Balloons
          • 3.1.1.1.4.2. Gastric Bands
          • 3.1.1.1.4.3. Stapling Devices
  • 3.2. Global Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Institutional Sales
        • 3.2.1.1.1. Hospitals
        • 3.2.1.1.2. Specialty Clinics
        • 3.2.1.1.3. Ambulatory Surgical Centers
      • 3.2.1.2. Retail Sales
        • 3.2.1.2.1. Retail Pharmacy
        • 3.2.1.2.2. Drug Stores
        • 3.2.1.2.3. Supermarkets / Hypermarkets
        • 3.2.1.2.4. Health & Beauty Stores
      • 3.2.1.3. Online Sales
  • 3.3. Global Overweight Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Overweight Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
        • 4.1.1.1.1. Drug Treatment
          • 4.1.1.1.1.1. Bupropion and Naltrexone
          • 4.1.1.1.1.2. Orlistat
          • 4.1.1.1.1.3. Phentermine and Topiramate
          • 4.1.1.1.1.4. Liraglutide
        • 4.1.1.1.2. Others
        • 4.1.1.1.3. Supplements
        • 4.1.1.1.4. Medical Devices / Implants
          • 4.1.1.1.4.1. Gastric Balloons
          • 4.1.1.1.4.2. Gastric Bands
          • 4.1.1.1.4.3. Stapling Devices
  • 4.2. North America Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Institutional Sales
        • 4.2.1.1.1. Hospitals
        • 4.2.1.1.2. Specialty Clinics
        • 4.2.1.1.3. Ambulatory Surgical Centers
      • 4.2.1.2. Retail Sales
        • 4.2.1.2.1. Retail Pharmacy
        • 4.2.1.2.2. Drug Stores
        • 4.2.1.2.3. Supermarkets / Hypermarkets
        • 4.2.1.2.4. Health & Beauty Stores
      • 4.2.1.3. Online Sales
  • 4.3. North America Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Overweight Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
        • 5.1.1.1.1. Drug Treatment
          • 5.1.1.1.1.1. Bupropion and Naltrexone
          • 5.1.1.1.1.2. Orlistat
          • 5.1.1.1.1.3. Phentermine and Topiramate
          • 5.1.1.1.1.4. Liraglutide
        • 5.1.1.1.2. Others
        • 5.1.1.1.3. Supplements
        • 5.1.1.1.4. Medical Devices / Implants
          • 5.1.1.1.4.1. Gastric Balloons
          • 5.1.1.1.4.2. Gastric Bands
          • 5.1.1.1.4.3. Stapling Devices
  • 5.2. Europe Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Institutional Sales
        • 5.2.1.1.1. Hospitals
        • 5.2.1.1.2. Specialty Clinics
        • 5.2.1.1.3. Ambulatory Surgical Centers
      • 5.2.1.2. Retail Sales
        • 5.2.1.2.1. Retail Pharmacy
        • 5.2.1.2.2. Drug Stores
        • 5.2.1.2.3. Supermarkets / Hypermarkets
        • 5.2.1.2.4. Health & Beauty Stores
      • 5.2.1.3. Online Sales
  • 5.3. Europe Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Overweight Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
        • 6.1.1.1.1. Drug Treatment
          • 6.1.1.1.1.1. Bupropion and Naltrexone
          • 6.1.1.1.1.2. Orlistat
          • 6.1.1.1.1.3. Phentermine and Topiramate
          • 6.1.1.1.1.4. Liraglutide
        • 6.1.1.1.2. Others
        • 6.1.1.1.3. Supplements
        • 6.1.1.1.4. Medical Devices / Implants
          • 6.1.1.1.4.1. Gastric Balloons
          • 6.1.1.1.4.2. Gastric Bands
          • 6.1.1.1.4.3. Stapling Devices
  • 6.2. Asia Pacific Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Institutional Sales
        • 6.2.1.1.1. Hospitals
        • 6.2.1.1.2. Specialty Clinics
        • 6.2.1.1.3. Ambulatory Surgical Centers
      • 6.2.1.2. Retail Sales
        • 6.2.1.2.1. Retail Pharmacy
        • 6.2.1.2.2. Drug Stores
        • 6.2.1.2.3. Supermarkets / Hypermarkets
        • 6.2.1.2.4. Health & Beauty Stores
      • 6.2.1.3. Online Sales
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Overweight Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
        • 7.1.1.1.1. Drug Treatment
          • 7.1.1.1.1.1. Bupropion and Naltrexone
          • 7.1.1.1.1.2. Orlistat
          • 7.1.1.1.1.3. Phentermine and Topiramate
          • 7.1.1.1.1.4. Liraglutide
        • 7.1.1.1.2. Others
        • 7.1.1.1.3. Supplements
        • 7.1.1.1.4. Medical Devices / Implants
          • 7.1.1.1.4.1. Gastric Balloons
          • 7.1.1.1.4.2. Gastric Bands
          • 7.1.1.1.4.3. Stapling Devices
  • 7.2. Latin America Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Institutional Sales
        • 7.2.1.1.1. Hospitals
        • 7.2.1.1.2. Specialty Clinics
        • 7.2.1.1.3. Ambulatory Surgical Centers
      • 7.2.1.2. Retail Sales
        • 7.2.1.2.1. Retail Pharmacy
        • 7.2.1.2.2. Drug Stores
        • 7.2.1.2.3. Supermarkets / Hypermarkets
        • 7.2.1.2.4. Health & Beauty Stores
      • 7.2.1.3. Online Sales
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Overweight Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
        • 8.1.1.1.1. Drug Treatment
          • 8.1.1.1.1.1. Bupropion and Naltrexone
          • 8.1.1.1.1.2. Orlistat
          • 8.1.1.1.1.3. Phentermine and Topiramate
          • 8.1.1.1.1.4. Liraglutide
        • 8.1.1.1.2. Others
        • 8.1.1.1.3. Supplements
        • 8.1.1.1.4. Medical Devices / Implants
          • 8.1.1.1.4.1. Gastric Balloons
          • 8.1.1.1.4.2. Gastric Bands
          • 8.1.1.1.4.3. Stapling Devices
  • 8.2. Middle East & Africa Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Institutional Sales
        • 8.2.1.1.1. Hospitals
        • 8.2.1.1.2. Specialty Clinics
        • 8.2.1.1.3. Ambulatory Surgical Centers
      • 8.2.1.2. Retail Sales
        • 8.2.1.2.1. Retail Pharmacy
        • 8.2.1.2.2. Drug Stores
        • 8.2.1.2.3. Supermarkets / Hypermarkets
        • 8.2.1.2.4. Health & Beauty Stores
      • 8.2.1.3. Online Sales
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Product vs by Distribution Channel Heatmap
  • 9.2. Company Market Share Analysis, 2022
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novo Nordisk A/S
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Therapy Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. VIVUS LLC
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Therapy Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. AstraZeneca
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Therapy Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Currax Pharmaceuticals LLC
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Therapy Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Spansules Pharmatech Pvt Ltd
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Therapy Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Atkins Nutritional Inc
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Therapy Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Apollo Endosurgery, Inc
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Therapy Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Herbalife Nutrition Ltd.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Therapy Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. SMP Nutra
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Therapy Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Allurion Technologies
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Therapy Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. ReShape Lifesciences, Inc
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Therapy Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations